Ocrelizumab biosimilar PB018

Ocrelizumab biosimilar PB018

Products

Information

Polpharma Biologics is developing a Ocrelizumab biosimilar under code name PB018. We are currently in the process of transferring the cell line and clone to our Gdansk facility to take it to the next stage of technical proof of similarity. We are seeking partners interested in marketing or licensing this biosimilar.
Polpharma BiologicsWe have developed an extensive and ever-growing pipeline of biosimilars to treat a number of conditions across major therapeutic areas. Many of these biosimilars have already been partnered, the most advanced of which are listed below. We consistently invest in the start of one biosimilar development per year based upon expert market analysis, clinical evaluation, and an extensive manufacturing assessment. The ultimate goal of our biosimilar development is to partner with companies that have the reach to maximize the access to patients who need such high-quality medicines. Biosimilars in our pipeline include Ranibizumab, Natalizumab, Tysabri, Vedolizumab, Ipilimumab, Ocrelizumab, Pembrolizumab, Nivolumab

Log in

See all the content and easy-to-use features by logging in or registering!